Skip to main content

Table 2 Antimicrobial susceptibility of MRSA strains isolated from cancer patients in this study

From: Prevalence of methicillin resistance and superantigenic toxins in Staphylococcus aureus strains isolated from patients with cancer

Antimicrobial category

Antimicrobial agents

Concentration of disk (μg)

Sensitive n (%)

Intermediate n (%)

Resistant n (%)

Anti-staphylococcal β-lactams (or cephamycins)

Cefoxitin (FOX)

30

–

–

29 (100%)

Folate pathway inhibitors

Cotrimoxazole (TS)

25

17 (58.6%)

2 (6.9%)

10 (34.5%)

Lincosamides

Clindamycin (CD)

2

7 (24.2%)

2 (6.8%)

20 (69%)

Glycopeptides

Teicoplanin (TEC)

30

25 (86.2%)

1 (3.4%)

3 (10.4%)

Tetracyclines

Tetracycline (TE)

10

12 (41.4%)

–

17 (58.6%)

Ansamycins

Rifampicin (RP)

5

12 (41.4%)

2 (6.8%)

15 (51.8%)

Macrolides

Erythromycin (E)

15

4 (13.8%)

1 (3.4%)

24 (82.8%)

Streptogramins

Quinupristin/dalfopristin (SYN)

15

21 (72.4%)

–

8 (27.6%)

Fluoroquinolones

Ciprofloxacin (CIP)

5

4 (13.8%)

–

25 (86.2%)

Oxazolidinones

Linezolid (LZD)

30

26 (89.6%)

–

3 (10.4%)